Chester County News and Community Website
WILMINGTON, DE — Incyte (Nasdaq: INCY) announced plans to participate in several investor conferences throughout September 2025.
Incyte to Present at Multiple Healthcare Investor Conferences in September Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) announced Monday that Christiana Stamoulis, Executive Vice President and Chief Financial Officer, will depart the company on September 16 to pursue another opportunity. Stamoulis will …
Incyte CFO Christiana Stamoulis to Step Down in September Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) delivered solid second-quarter results, reporting a 17% year-over-year increase in product revenues to $1.06 billion and raising its full-year 2025 guidance for multiple products, …
Incyte Reports Strong Q2 Growth and Raises Full-Year Guidance on Robust Product Sales and Pipeline Progress Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) will present new clinical data from its oncology pipeline at the upcoming European Society of Medical Oncology (ESMO) Congress, set for October 17–21 in Berlin. …
Incyte to Spotlight Next-Generation Cancer Therapies at ESMO 2025 Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) will host its second quarter financial results conference call and webcast on Tuesday, July 29, 2025, at 8:00 a.m. ET.
Incyte Announces Q2 2025 Financial Results Call and Webcast Details Read More WILMINGTON, DE — Incyte Corporation (Nasdaq: INCY) announced equity inducement award grants to Bill Meury following his recent appointment as the Company’s new President and CEO. The awards were granted …
Incyte Announces Equity Awards for New CEO Bill Meury with Performance-Based Incentives Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) has named Bill Meury as its new President and Chief Executive Officer (CEO) and elected him to the company’s Board of Directors, effective immediately. …
Bill Meury Named President and CEO of Incyte Read More WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has announced a three-month extension for its review of the supplemental New Drug Application (sNDA) for ruxolitinib cream (Opzelura®), submitted …
FDA Extends Review Period for Ruxolitinib Cream for Pediatric Atopic Dermatitis Read More WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix) in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory …
FDA Approves Monjuvi for Treating Relapsed or Refractory Follicular Lymphoma Read More VENLO, Netherlands & WILMINGTON, DE — QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) have announced a global collaboration to create a next-generation sequencing (NGS) diagnostic …
QIAGEN and Incyte Partner to Develop NGS Diagnostic Panel for Rare Blood Cancers Read More